Hemispherx is committed to advancing our technology platforms and product candidates.  In order to pursue this goal, Hemispherx is highly interested in collaborative opportunities including product out-licensing, co-research, co-development, co-promotion, and co-marketing with research institutes, pharmaceutical companies, and biotech companies domestically and internationally.

  • Ampligen
    • Chronic Fatigue Syndrome (CFS)
    • Cancer
    • Vaccine Adjuvant
    • Broad Spectrum Antiviral
    • Traumatic Injury / Burns Immunodeficiency
  • Alferon
    • Broad Spectrum Antiviral
    • Genital Warts
    • Anti-Cancer
    • Argentina Approval
      • Intralesional treatment of external genital warts refractory or recurring
      • Treatment patients who initially responded to recombinant interferon alpha, including pegylated interferon alfa, but later treatment failed due to the presence of neutralizing antibodies.

Contact Us

Please direct your inquiries regarding business development and licensing opportunities to: BD@hemispherx.net

Site Map | Privacy | Terms Of Use Copyright   Hemispherx Biopharma, Inc. | All Rights Reserved.